Table 15 Drug treatment strategies for metastatic or unresectable non-clear cell type renal cell carcinoma

(recommended for first choice of clinical studies in any of the following situations)

Treatment status

Stratification

Tier I Specialist Recommendation

Tier II Specialist Recommendation

III Specialist Recommendation

First-line treatment

Non-collecting ductal carcinoma

Clinical studies

Sunitinib (Evidence 2A)
Everolimus (2A evidence)
Tesilomox (2A evidence)
Cabozantinib (2A evidence)

Sorafenib
pegaptanib (evidence)
Axitinib

Collecting duct cancer

Clinical studies

Gicitabine + cisplatin
Sorafenib + gemcitabine + cisplatin